knowledge -WSS

knowledge

author：focus 2025-09-14 11:46:56 - browse：9

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Making AI in medicine accessible to smaller, and rural hospitals

explore

WSS

Use wet bulb globe temperature, not heat index, to protect workers

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

How the drug

Bird flu outbreak in cows is latest avian flu curveball

After gene therapy, two congenitally deaf children hear for the first time

Software glitch causes Tandem insulin pump to shutdown, FDA warns

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Malaria cases in Florida and Texas: Here’s what you need to know

Roche's accidental data boosts hopes for anti

What does generative AI mean for health care? We asked experts

Study: Spinal cord stimulation helps patients with paralysis walk again

Novavax promises a turnaround & Lilly roils the obesity market

Former Pear Therapeutics executives start new VC firm

Novavax promises a turnaround & Lilly roils the obesity market

Use wet bulb globe temperature, not heat index, to protect workers

Drug repurposing or repositioning? The language matters

CDC wastewater surveillance dashboard to track bird flu hotspots

entertainment

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Sanofi strikes deal with Novavax, boosting the vaccine maker

Trans patients at the end of life deserve respect and dignity

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

FDA greenlights medical device to combat bladder issues

Dairy farmers resist CDC push for PPE against bird flu virus

explore

knowledge

explore

explore